Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1).

Poeppel, T D; Boy, Christian; Bockisch, A; Kotzerke, J; Buchmann, I; Ezziddin, S; Scheidhauer, K; Krause, B J; Schmidt, D; Amthauer, H; Rösch, F; Nagarajah, J; Führer, D; Lahner, H; Pöpperl, G; Hörsch, D; Walter, Martin Alexander; Baum, R P (2015). Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin / Nuclear medicine, 54(1), pp. 1-11. Schattauer

Text Peptid-Rezeptor-Radionuklid-Therapie (PRRT) Somatostatin Rezeptor exprimierender Tumore_WAL.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (206kB)

This document describes the guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the official AWMF Guideline Registry. These recommendations are a prerequisite for the quality management in the treatment of patients with somatostatin receptor expressing tumours using PRRT. They are aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRT and to deliver the treatment in a safe and effective manner. The recommendations are based on an interdisciplinary consensus. The document contains background information and definitions and covers the rationale, indications and contraindications for PRRT. Essential topics are the requirements for institutions performing the therapy, e. g. presence of an expert for medical physics, intense cooperation with all colleagues involved in the treatment of a patient, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with the involved medical disciplines. Generally, the decision for PRRT should be undertaken within the framework of a multi-disciplinary tumour board.

Interest & Impact

Downloads

3 since deposited on 31 Mar 2015
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item